Boardroom Alpha
Boardroom Alpha
CME · Current Report (Form 8-K) · Filed April 27, 2026

Cme Group Inc — Current Report (Form 8-K)

Form
8-K
Filed
April 27, 2026
Period
Apr 22, 2026
Ticker
CME
Accession
0001156375-26-000022
Boardroom Alpha · Filing insights

CME amended its $7B 364-day credit facility to bolster liquidity for clearing operations, with potential increase to $10B.

About Cme Group Inc
Market cap
$90.8B
1Y TSR
+7.7%
3Y TSR
+21.1%
Board grade
B-
Sector
Financial Services
CEO
Terrence A Duffy
Last annual meeting: May 14, 2026 · View full Cme Group Inc profile →
cme-20260422

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549 
_________________________________________________________
FORM 8-K
 
_________________________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) April 27, 2026 (April 22, 2026)
 
 _________________________________________________________
CME GROUP INC.
(Exact Name of Registrant as Specified in its Charter) 
_________________________________________________________ 
Delaware 001-31553 36-4459170
(State or Other Jurisdiction
of Incorporation)
 (Commission
File No.)
 (IRS Employer
Identification No.)
 
20 South Wacker DriveChicagoIllinois 60606
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (312) 930-1000
N/A
(Former Name or Former Address, if Changed Since Last Report) 
______________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered
Class A Common StockCMENasdaq
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405) of this chapter or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐



If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.01Entry into a Material Definitive Agreement.
Clearing House Credit Facility

Effective as of April 22, 2026, Chicago Mercantile Exchange Inc. ("CME") entered into an amendment ("Amendment No. 11") to its 364-day multi-currency credit facility (the "364-Day Credit Facility") with Bank of America, N.A., in its capacity as Administrative Agent, Citibank, N.A., in its capacity as Collateral Agent and Collateral Monitoring Agent, and the banks party thereto. The 364-Day Credit Facility as amended by Amendment No. 11 is referred to as the "Existing 364-Day Credit Facility."

The Existing 364-Day Credit Facility is for a multi-currency revolving secured credit facility of $7 billion (which is eligible to be increased to $10 billion). The proceeds of the Existing 364-Day Credit Facility may be used to provide temporary liquidity in the unlikely event a clearing firm fails to promptly discharge an obligation to the clearing house operated by CME, in the event of a liquidity constraint or default by a depositary (custodian for our collateral), in the event of a temporary disruption with the domestic payments system that would delay payment of settlement variation between CME and its clearing firms, or in other cases as provided by the CME rulebook. Clearing firm guaranty fund contributions received in the form of cash or U.S. Treasury securities as well as the performance bond assets (pursuant to the CME rulebook) can be used to collateralize the facility. The Existing 364-Day Credit Facility contains a requirement that CME remain in compliance with a consolidated tangible net worth test.

The foregoing description of the Existing 364-Day Credit Facility is only a summary, does not purport to be complete and is qualified in its entirety by reference to, and should be read in conjunction with, the complete text of the Existing 364-Day Credit Facility, which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.

 

Item 9.01Financial Statements and Exhibits.
    
Exhibit
Number    
  Description
10.1
104The cover page from CME Group Inc.’s Current Report on Form 8-K, formatted in Inline XBRL.




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



 
 CME Group Inc.
 Registrant
Date: April 27, 2026 By: /s/ Lynne Fitzpatrick
 Name:

Title:
 Lynne Fitzpatrick

Senior Managing Director, President and Chief Financial Officer

Principal Financial Offer and
Duly Authorized Officer
  

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Cme Group Inc (CME)

Reference

Frequently asked questions

When did Cme Group Inc file this 8-K?
Cme Group Inc (CME) filed this Current Report (Form 8-K) with the SEC on April 27, 2026. The accession number assigned by EDGAR is 0001156375-26-000022.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
CME amended its $7B 364-day credit facility to bolster liquidity for clearing operations, with potential increase to $10B. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Cme Group Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Cme Group Inc has filed under CIK 1156375, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer